NR4A1 and breast cancer: In terms of clinicopathological features, as shown in prior studies9–12, the majority of breast cancer cases associated with germline BRCA1 pathogenic variants were hormone receptor-negative tumors (76%) while those arising in BRCA2-mutated patients were hormone receptor-positive (83%).